Which drug requires administration through a CVL with a potential for cryotherapy?

Daunorubicin is a chemotherapeutic agent that requires administration through a central venous line (CVL) due to its potential for causing severe tissue damage and necrosis if extravasated. The need for a CVL is based on the drug's irritant or vesicant properties, which can lead to significant complications if the drug leaks out of the vein during administration.

Additionally, the mention of cryotherapy relates to a practice often utilized to mitigate the effects of extravasation. Cryotherapy involves the application of cold packs to the area prior to and sometimes after infusion to reduce blood flow, thereby minimizing potential tissue damage and inflammatory response from extravasation incidents.

Dactinomycin, cyclophosphamide, and clofarabine have different routes of administration and safety profiles. Dactinomycin may be given IV but typically isn’t classified in the same category as requiring CVL; cyclophosphamide is administered by various routes with a good safety profile compared to drugs that require a CVL; and clofarabine also has specific guidelines for administration but does not usually necessitate a CVL for administration. Understanding the specific handling and safety considerations for each drug is crucial in the management of chemotherapy.